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Background
Enzalutamide is an oral androgen-receptor inhibitor that prolongs survival in men 
with metastatic castration-resistant prostate cancer in whom the disease has pro-
gressed after chemotherapy. New treatment options are needed for patients with 
metastatic prostate cancer who have not received chemotherapy, in whom the dis-
ease has progressed despite androgen-deprivation therapy.
Methods
In this double-blind, phase 3 study, we randomly assigned 1717 patients to receive 
either enzalutamide (at a dose of 160 mg) or placebo once daily. The coprimary end 
points were radiographic progression-free survival and overall survival.
Results
The study was stopped after a planned interim analysis, conducted when 540 deaths 
had been reported, showed a benefit of the active treatment. The rate of radio-
graphic progression-free survival at 12 months was 65% among patients treated 
with enzalutamide, as compared with 14% among patients receiving placebo (81% 
risk reduction; hazard ratio in the enzalutamide group, 0.19; 95% confidence inter-
val [CI], 0.15 to 0.23; P<0.001). A total of 626 patients (72%) in the enzalutamide 
group, as compared with 532 patients (63%) in the placebo group, were alive at the 
data-cutoff date (29% reduction in the risk of death; hazard ratio, 0.71; 95% CI, 
0.60 to 0.84; P<0.001). The benefit of enzalutamide was shown with respect to all 
secondary end points, including the time until the initiation of cytotoxic chemo-
therapy (hazard ratio, 0.35), the time until the first skeletal-related event (hazard 
ratio, 0.72), a complete or partial soft-tissue response (59% vs. 5%), the time until 
prostate-specific antigen (PSA) progression (hazard ratio, 0.17), and a rate of de-
cline of at least 50% in PSA (78% vs. 3%) (P<0.001 for all comparisons). Fatigue and 
hypertension were the most common clinically relevant adverse events associated 
with enzalutamide treatment.
Conclusions
Enzalutamide significantly decreased the risk of radiographic progression and 
death and delayed the initiation of chemotherapy in men with metastatic prostate 
cancer. (Funded by Medivation and Astellas Pharma; PREVAIL ClinicalTrials.gov 
number, NCT01212991.)
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Prostate cancer is the most common-ly diagnosed cancer and the sixth leading cause of cancer-related death among men 
worldwide.1 Strategies to block androgen-recep-
tor signaling have formed the backbone of pros-
tate-cancer therapy since the first description of 
the hormonal dependence of this cancer in 1941.2 
Advances in endocrine therapies have improved 
survival in men with high-risk locoregional pros-
tate cancer.3,4 However, new hormonal agents 
have been shown to extend survival in men with 
metastatic castration-resistant disease.5-9
In most patients who are treated for advanced 
recurrent prostate cancer with androgen-depri-
vation therapy (comprising a luteinizing hormone–
releasing hormone [LHRH] analogue or orchiec-
tomy with or without an antiandrogen), disease 
progression occurs despite effective suppression 
of serum testosterone. This disease state, called 
castration-resistant prostate cancer, is almost 
always associated with increases in levels of se-
rum prostate-specific antigen (PSA), suggesting 
that the disease continues to be driven by andro-
gen-receptor signaling. Preclinical evidence sug-
gests that androgen-receptor overexpression is 
sufficient to confer resistance to androgen de-
privation in prostate-cancer cell lines10,11 and 
that levels of intratumoral androgens are often 
increased in patients with progressive prostate 
cancer.12 These observations have provided a 
clear basis for developing more effective meth-
ods to treat prostate cancer by further suppress-
ing androgen-receptor signaling.13,14
Enzalutamide (formerly known as MDV3100) 
is a rationally designed, targeted androgen-recep-
tor inhibitor that competitively binds to the li-
gand-binding domain of the androgen receptor 
and inhibits androgen-receptor translocation to 
the cell nucleus, recruitment of androgen-recep-
tor cofactors, and androgen-receptor binding to 
DNA.15 In a phase 1–2 trial, enzalutamide was 
found to have encouraging antitumor activity in 
men with castration-resistant prostate cancer, with 
data suggesting a greater benefit in men who had 
not yet received chemotherapy.16 In a previous 
phase 3 study, enzalutamide, as compared with 
placebo, prolonged overall and progression-free 
survival, improved patient-reported quality of life, 
and delayed the development of skeletal-related 
complications in men with metastatic castration-
resistant prostate cancer who had previously re-
ceived docetaxel.7 In our study, we evaluated 
enzalutamide in men in whom hormonal agents 
are frequently administered (i.e., those who have 
asymptomatic or mildly symptomatic metastatic 
disease that has progressed despite the use of 
androgen-deprivation therapy) and who have not 
undergone chemotherapy.
Me thods
Study Design and Conduct
The PREVAIL study was a multinational, double-
blind, randomized, placebo-controlled, phase 3 
trial of enzalutamide. The study was approved by 
the independent review board at each participat-
ing site and was conducted according to the pro-
visions of the Declaration of Helsinki and the 
Good Clinical Practice Guidelines of the Interna-
tional Conference on Harmonisation. All patients 
provided written informed consent before par-
ticipating in the trial. An independent data and 
safety monitoring committee reviewed safety data 
at regular intervals and reviewed the prespecified 
interim analysis conducted by an independent 
statistical group at the contract clinical research 
organization where the study database was held.
The study was designed by prostate-cancer 
experts and employees of the sponsors, Mediva-
tion and Astellas Pharma, which are codevelop-
ing enzalutamide. Investigators at the participat-
ing centers entered the data into an electronic 
data-capture system that was verified for source 
data by monitors from a separate clinical research 
organization. The data analyses reported here 
were conducted by the sponsor and were provided 
to all the authors, who wrote the manuscript and 
made the decision to submit the manuscript for 
publication. These authors assume responsibility 
for the accuracy of the data and adherence to the 
study protocol, which is available with the full 
text of this article at NEJM.org. A professional 
writer who was paid by the sponsors assisted in 
the preparation of the manuscript. All the authors 
and participating institutions have agreements 
with the sponsors regarding the confidentiality 
of the data.
Study Participants
Patients were eligible if they had histologically or 
cytologically confirmed adenocarcinoma of the 
prostate with documented metastases and had 
PSA progression, radiographic progression, or both 
in bone or soft tissue, despite receiving LHRH 
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analogue therapy or undergoing orchiectomy, 
with a serum testosterone level of 1.73 nmol per 
liter (50 ng per deciliter) or less. Continued an-
drogen-deprivation therapy was required. Previous 
antiandrogen therapy and concurrent use of glu-
cocorticoids were permitted but not required. 
Eligible patients had not received cytotoxic che-
motherapy, ketoconazole, or abiraterone acetate, 
had an Eastern Cooperative Oncology Group per-
formance status grade of 0 or 1 (no symptoms or 
ambulatory but restricted in strenuous activities), 
and were either asymptomatic (score of 0 to 1) or 
mildly symptomatic (score of 2 to 3), as measured 
on the Brief Pain Inventory Short Form question 
3 (on which scores range from 0 to 10, with high-
er scores indicating a greater severity of pain). 
Patients with visceral disease, including lung or 
liver metastases, were eligible, as were patients 
with New York Heart Association class I or II 
heart failure. Patients with a history of seizure or 
a condition that could confer a predisposition to 
seizure were excluded, although patients taking 
medications associated with lowering the seizure 
threshold were eligible.
From September 2010 through September 2012, 
patients were enrolled at 207 sites globally. All 
patients were randomly assigned to receive either 
oral enzalutamide (at a dose of 160 mg) or placebo 
once daily with or without food. Randomization 
was stratified according to the study site. Treat-
ment continued until the occurrence of unaccept-
able side effects or confirmed radiographic pro-
gression and the initiation of chemotherapy or 
an investigational agent. Treatment discontinua-
tion because of an increase in the PSA level alone 
was discouraged.
Study End Points
Coprimary end points were radiographic progres-
sion-free survival and overall survival. Secondary 
end points included the time until the initiation 
of cytotoxic chemotherapy, the time until the first 
skeletal-related event, the best overall soft-tissue 
response, the time until PSA progression, and a 
decline in the PSA level of 50% or more from 
baseline. Prespecified exploratory end points in-
cluded quality of life, as measured with the use 
of the Functional Assessment of Cancer Therapy–
Prostate (FACT-P) scale, and a decline in the PSA 
level of 90% or more from baseline. End-point 
definitions are provided in Table S1 in the Sup-
plementary Appendix, available at NEJM.org.
Radiographic disease was evaluated with the 
use of either computed tomography or magnetic 
resonance imaging and with the use of bone 
scanning. Imaging was performed at the time of 
screening, at weeks 9, 17, and 25, and every 12 
weeks thereafter. Radiologists at a central location 
who were unaware of the study-group assign-
ments determined whether there was progres-
sive disease on the basis of Response Evaluation 
Criteria in Solid Tumors (RECIST), version 1.1, for 
soft tissue or on the basis of criteria adapted 
from the Prostate Cancer Clinical Trials Working 
Group 217 for osseous disease (Table S1 in the 
Supplementary Appendix).
Statistical Analysis
The planned enrollment was approximately 1680 
patients. The coprimary end points were ana-
lyzed in the intention-to-treat population at a to-
tal type I error rate of 0.05, with an error rate of 
0.001 (two-sided) allocated to radiographic pro-
gression-free survival and an error rate of 0.049 
(two-sided) allocated to overall survival. It was 
planned that the final analysis of radiographic 
progression-free survival would be conducted af-
ter the occurrence of at least 410 events at the 
time of the interim analysis of overall survival. 
The interim analysis of overall survival was to be 
conducted after the occurrence of approximately 
516 deaths, or 67% of the 765 deaths specified 
for the final analysis. The final analysis of radio-
graphic progression-free survival was performed 
after the occurrence of 439 events (with data cut-
off on May 6, 2012); the interim analysis of over-
all survival was performed after the occurrence 
of 540 deaths with the use of a two-sided type I 
error rate of 0.0147. Holm’s step-down procedure 
was applied to the analyses of the secondary end 
points to maintain a two-sided type I error of 5%.18 
The results presented here are based on a cutoff 
date of September 16, 2013, unless otherwise 
specified. An updated survival analysis was per-
formed with a data-cutoff date of January 15, 2014.
R esult s
Study Patients
A total of 1717 patients were enrolled in the 
study, with 872 in the enzalutamide group and 
845 in the placebo group; 1715 patients received 
at least one dose of a study drug (Fig. S1 in the 
Supplementary Appendix). Baseline demographic 
and disease characteristics were well balanced 
between the two groups (Tables S2 and S3 in the 
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Supplementary Appendix). The median time that 
patients received a study drug was substantially 
longer in the enzalutamide group than in the pla-
cebo group (16.6 months vs. 4.6 months). More 
patients in the enzalutamide group than in the 
placebo group received at least 12 months of treat-
ment (68% vs. 18%) and continued to receive treat-
ment as of the data-cutoff date (42% vs. 7%).
Coprimary End Points
Radiographic Progression-free Survival
At 12 months of follow-up, the rate of radiographic 
progression-free survival was 65% in the enzalu-
tamide group and 14% in the placebo group. 
Treatment with enzalutamide, as compared with 
placebo, resulted in an 81% reduction in the risk 
of radiographic progression or death (hazard ra-
tio in the enzalutamide group, 0.19; 95% confi-
dence interval [CI], 0.15 to 0.23; P<0.001) (Fig. 1A). 
Fewer patients in the enzalutamide group than 
in the placebo group had radiographic progres-
sion or died (118 of 832 patients [14%] vs. 321 of 
801 patients [40%]). The median radiographic 
progression-free survival was not reached in the 
enzalutamide group, as compared with 3.9 months 
in the placebo group. The treatment effect of 
enzalutamide on radiographic progression-free 
survival was consistent across all prespecified sub-
groups (Fig. S2 in the Supplementary Appendix).
Overall Survival
At the planned interim analysis of overall sur-
vival, the median duration of follow-up for sur-
vival was approximately 22 months. Fewer deaths 
occurred in the enzalutamide group than in the 
placebo group (241 of 872 patients [28%] vs. 299 
of 845 patients [35%]). Treatment with enzalu-
tamide, as compared with placebo, resulted in a 
29% decrease in the risk of death (hazard ratio, 
0.71; 95% CI, 0.60 to 0.84; P<0.001) (Fig. 1B). The 
median overall survival was estimated at 32.4 
months in the enzalutamide group and 30.2 
months in the placebo group. The treatment ef-
fect of enzalutamide on overall survival was con-
sistent across all prespecified subgroups (Fig. S3 
in the Supplementary Appendix). The risk reduc-
tions for both coprimary end points were unaf-
fected by previous exposure to antiandrogens. 
After review of the interim coprimary efficacy 
and safety results, the data and safety monitor-
ing committee recommended halting the study 
and offering enzalutamide to eligible patients re-
ceiving placebo. An updated analysis of overall 
survival with 116 additional deaths showed that 
82% of patients in the enzalutamide group and 
73% of those in the placebo group were alive at 
18 months; the estimated median was not yet 
reached in the enzalutamide group and was 31.0 
months in the placebo group (hazard ratio, 0.73; 
95% CI, 0.63 to 0.85; P<0.001) (Table S4 in the 
Supplementary Appendix).
Subsequent Antineoplastic Therapy
Subsequent antineoplastic treatments associated 
with a demonstrated survival benefit in meta-
static prostate cancer were received by 40% of 
patients in the enzalutamide group, as compared 
with 70% of those in the placebo group. The two 
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Figure 1. Kaplan–Meier Estimates of Radiographic Progression-free Survival 
and Overall Survival.
Shown are data for the coprimary end points of radiographic progression-
free survival (Panel A) and overall survival (Panel B). The dashed horizontal 
lines indicate medians. Hazard ratios are based on unstratified Cox regres-
sion models with treatment as the only covariate, with values of less than 
1.00 favoring enzalutamide.
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most common subsequent therapies were docetax-
el (received by 33% and 57% of patients, respec-
tively) and abiraterone (received by 21% and 46%, 
respectively) (Table S5 in the Supplementary Ap-
pendix). The use of abiraterone was more com-
mon in North America than in other regions. The 
duration and efficacy of post-progression thera-
pies were not ascertained.
Prespecified Secondary and Exploratory  
End Points
The superiority of enzalutamide over placebo was 
shown with respect to all secondary end points. 
The median time until the initiation of cytotoxic 
chemotherapy was 28.0 months in the enzalu-
tamide group, as compared with 10.8 months in 
the placebo group (hazard ratio, 0.35; P<0.001) 
(Table 1 and Fig. 2A). Treatment with enzalu-
tamide also resulted in a reduction in the risk of 
a first skeletal-related event, which occurred in 
278 patients (32%) in the enzalutamide group 
and 309 patients (37%) in the placebo group 
(hazard ratio, 0.72; P<0.001) at a median of ap-
proximately 31 months in each of the two groups 
(Table 1).
Among patients with measurable soft-tissue 
disease at baseline, 59% of the patients in the 
enzalutamide group, as compared with 5% in 
the placebo group, had an objective response 
(P<0.001) (Table 1): complete and partial re-
sponses were observed in 20% and 39% of the 
patients, respectively, in the enzalutamide group, 
as compared with 1% and 4%, respectively, in 
the placebo group. Enzalutamide was also supe-
Table 1. Secondary and Prespecified Exploratory End Points.*
End Point
Enzalutamide  
(N = 872)
Placebo  
(N = 845)
Hazard Ratio  
(95% CI) P Value
Median time until initiation of cytotoxic 
chemotherapy — mo
28.0 10.8 0.35 (0.30–0.40) <0.001
Median time until decline in the FACT-P 
global score — mo†‡
11.3 5.6 0.63 (0.54–0.72) <0.001
Median time until first skeletal-related event 
— mo§
31.1 31.3 0.72 (0.61–0.84) <0.001
Median time until PSA progression — mo¶ 11.2 2.8 0.17 (0.15–0.20) <0.001
Confirmed change in PSA‖
Patients with ≥1 post-baseline PSA 
assessment — no. (%)
854 (98) 777 (92)
PSA decline of ≥50% from baseline — 
no./total no. (%)
666/854 (78) 27/777 (3) <0.001
PSA decline of ≥90% from baseline — 
no./total no. (%)†
400/854 (47) 9/777 (1) <0.001
Patients with measurable soft-tissue 
disease — no. (%)**║
396 (45) 381 (45)
Objective response 233 (59) 19 (5) <0.001
Complete response 78 (20) 4 (1)
Partial response 155 (39) 15 (4)
* A complete definition of study end points is provided in Table S1 in the Supplementary Appendix. CI denotes confi-
dence interval, and PSA prostate-specific antigen.
† This category was a prespecified exploratory end point.
‡ A decline on the Functional Assessment of Cancer Therapy–Prostate (FACT-P) scale was defined as decrease of 10 
points or more on the global score, which ranges from 0 to 156, with higher scores indicating a better quality of life.
§ The hazard ratio is a more accurate measure of treatment effect than are estimates of the median time until the event 
for late-occurring events in this study.
¶ PSA progression was based on criteria of the Prostate Cancer Clinical Trials Working Group 2.
‖ Only patients with baseline and post-baseline assessments are included.
** Only patients with measurable soft-tissue disease at baseline, as assessed on the basis of the Response Evaluation 
Criteria in Solid Tumors, version 1.1, are included.
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rior to placebo with respect to reductions of at 
least 50% and 90% in the PSA level, the time 
until PSA progression, and the time until a de-
cline in the quality of life (Table 1 and Fig. 2B). 
The median time until a quality-of-life deteriora-
tion, as measured on the FACT-P scale, was 11.3 
months in the enzalutamide group and 5.6 
months in the placebo group (hazard ratio, 0.63; 
P<0.001).
Safety
Adverse events are summarized in Tables 2 and 3 
(with events occurring in at least 10% of patients 
in the enzalutamide group listed in the latter ta-
ble). The median reporting period for adverse 
events was 17.1 months in the enzalutamide 
group and 5.4 months in placebo group, which 
reflected the longer exposure of patients to 
enzalutamide. A grade 3 or higher adverse event 
was reported in 43% of the patients in the enzalu-
tamide group, as compared with 37% in the pla-
cebo group; however, the median time until the 
first event of grade 3 or higher was 22.3 months 
in the enzalutamide group and 13.3 months in 
the placebo group (Fig. S4 in the Supplementary 
Appendix). The most common adverse events 
leading to death were disease progression and a 
general deterioration in physical health, with 
similar incidences in the two groups.
Adverse events that occurred in 20% or more 
of patients receiving enzalutamide at a rate that 
was at least 2 percentage points higher than that 
in the placebo group were fatigue (Table S6 in 
the Supplementary Appendix), back pain, consti-
pation, and arthralgia. After adjustment for the 
length of exposure, events with a higher rate in 
the enzalutamide group than in the placebo 
group were hot flush (14 vs. 12 events per 100 
patient-years), hypertension (11 vs. 7 events per 
100 patient-years), and falls (11 vs. 9 events per 
100 patient-years). The most common event of 
grade 3 or higher in the enzalutamide group was 
hypertension, which was reported in 7% of the 
patients. The most common cardiac event was 
atrial fibrillation, which was reported in 2% of 
the patients in the enzalutamide group and in 
1% of those in the placebo group. One patient 
in each study group had a seizure. No evidence of 
hepatotoxicity, as measured by adverse events 
or laboratory assessments, was observed in the 
enzalutamide group.
Discussion
In our study involving men with metastatic pros-
tate cancer who had not received previous che-
motherapy, enzalutamide extended the time until 
radiographic progression or death, improved 
overall survival, and delayed the initiation of che-
motherapy by a median of 17 months. The ben-
efit of enzalutamide on radiographic progres-
sion-free survival was observed from the first 
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Figure 2. Kaplan–Meier Estimates for the Times until the Initiation of  
Cytotoxic Chemotherapy and an Increased Level of Prostate-Specific  
Antigen.
Shown are secondary efficacy end points that include the time until the 
initiation of cytotoxic chemotherapy (Panel A) and the time until an in-
creased level of prostate-specific antigen (PSA) (Panel B). The horizontal 
dashed lines indicate medians. Hazard ratios are based on unstratified Cox 
regression models with treatment as the only covariate, with values of less 
than 1.00 favoring enzalutamide. The full definition of PSA progression is 
provided in Table S1 in the Supplementary Appendix.
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assessment 2 months after randomization and 
conferred a relative reduction of 81% in the risk 
of progression or death. Consistent benefit was 
observed in all prespecified subgroups, including 
patients with visceral disease, a population with 
a poorer prognosis that has been excluded from 
other trials involving men with metastatic pros-
tate cancer who have not received previous che-
motherapy.8,19
Enzalutamide significantly reduced the risk 
of death by 29% over placebo, even though pa-
tients in the placebo group had received effective 
post-progression therapy more frequently and 
earlier than those in the enzalutamide group. 
The benefit of enzalutamide was observed as 
early as 4 months after randomization and was 
maintained throughout the study, as depicted by 
the separation in the Kaplan–Meier survival 
curves (Fig. 1B). At the time the trial was halted, 
following the interim analysis, the median fol-
low-up for survival was 22 months, approxi-
mately 8 to 10 months shorter than the esti-
mated survival medians. Because less than 5% 
of the patients were at risk when the estimated 
medians were reached, the hazard ratio, which 
analyzes the differences in outcome across the 
entire follow-up period, is a more accurate char-
acterization of the survival benefit and other 
late-occurring end points than is the estimate of 
the median time until the event.
Health-related quality-of-life assessments can 
reinforce and augment objective measures such 
as overall survival and radiographic progression. 
In this population of men with metastatic pros-
tate cancer, deterioration in the quality of life 
was delayed by enzalutamide, a result suggest-
ing that the treatment effects translated into 
patient-perceived benefits.
The benefit of enzalutamide was achieved 
with a favorable safety profile. Grade 3 or higher 
adverse events were more common in enzalu-
tamide-treated patients than in placebo-treated 
patients (43% vs. 37%), a finding that was prob-
ably influenced by the fact that the safety-report-
ing period for the enzalutamide group was ap-
proximately 1 year longer than that for the 
placebo group. The safety profile is further il-
lustrated by the 9-month delay in the median 
time until the first adverse event of grade 3 or 
higher in the enzalutamide group. A similar 
proportion of patients in each group (6%) dis-
continued treatment because of an adverse event.
The safety profile was generally consistent 
with that previously reported for enzalutamide 
in patients who had received previous chemo-
therapy, with a few exceptions.7 Seizure, which 
was previously observed in the enzalutamide 
group among patients who had received chemo-
therapy, occurred in a single patient (0.1%) in 
each group in our study. Both patients had a 
history of seizure that was unknown to investi-
gators at the time of enrollment. Hypertension 
was more commonly observed in the enzalu-
tamide group than in the placebo group (13% 
vs. 4%) and occurred more often in patients with 
a medical history of hypertension. These events 
were not associated with symptoms of mineralo-
corticoid excess or an increased risk of cardio-
vascular or renal sequelae and generally were 
managed with the use of standard therapies. In 
contrast to other antiandrogens, enzalutamide 
was not associated with hepatotoxicity. Other 
adverse events that were reported more frequent-
ly in the enzalutamide group than in the placebo 
group included fatigue or asthenia, back pain, 
hot flush, and falls.
Table 2. Summary of Adverse Events.
Variable
Enzalutamide 
(N = 871)
Placebo 
(N = 844)
Median safety reporting period — mo 17.1 5.4
Any adverse event — no. (%) 844 (97) 787 (93)
Any grade ≥3 adverse event — no. (%) 374 (43) 313 (37)
Median time until first grade ≥3 adverse event — mo 22.3 13.3
Any serious adverse event — no. (%) 279 (32) 226 (27)
Any adverse event leading to treatment discontinuation — no. (%) 49 (6) 51 (6)
Any adverse event leading to death — no. (%) 37 (4) 32 (4)
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Although chemotherapy has been shown to 
improve overall and progression-free survival in 
men with metastatic prostate cancer,20,21 many 
patients do not receive such therapy primarily 
because of preexisting medical conditions or as-
sociated toxic effects.22-24 Thus, there is a need 
for effective, convenient, and less toxic thera-
pies. Sipuleucel-T showed an overall survival 
advantage in asymptomatic or mildly symptom-
atic men, most of whom had not received che-
motherapy, but did not induce tumor responses 
or delay disease progression or deterioration in 
quality of life.19 Radium-223 was recently shown 
to extend survival in men with symptomatic 
castration-resistant prostate cancer and bone 
metastases.25 Abiraterone plus prednisone, which 
was recently compared with prednisone in pa-
tients with metastatic prostate cancer 8 who had 
not received chemotherapy, improved progres-
sion-free survival, lengthened the time until a 
quality-of-life deterioration, delayed chemother-
apy use, and was associated with a trend in favor 
of an overall survival benefit that did not reach 
statistical significance. Treatment with abira-
terone requires concomitant use of prednisone 
to ameliorate symptoms of mineralocorticoid 
excess, including fluid overload, hypokalemia, 
and hypertension.8,9
Multiple agents are now reported to improve 
survival for patients with metastatic prostate can-
Table 3. Most Common Adverse Events and Events of Special Interest.
Adverse Events
Enzalutamide
(N = 871)
Placebo
(N = 844)
All Grades Grade ≥3 All Grades Grade ≥3
number of patients (percent)
Most common adverse events*
Fatigue 310 (36) 16 (2) 218 (26) 16 (2)
Back pain 235 (27) 22 (3) 187 (22) 25 (3)
Constipation 193 (22) 4 (<1) 145 (17) 3 (<1)
Arthralgia 177 (20) 12 (1) 135 (16) 9 (1)
Decreased appetite 158 (18) 2 (<1) 136 (16) 6 (1)
Hot flush 157 (18) 1 (<1) 65 (8) 0
Diarrhea 142 (16) 2 (<1) 119 (14) 3 (<1)
Hypertension 117 (13) 59 (7) 35 (4) 19 (2)
Asthenia 113 (13) 11 (1) 67 (8) 8 (1)
Fall 101 (12) 12 (1) 45 (5) 6 (1)
Weight loss 100 (11) 5 (1) 71 (8) 2 (<1)
Edema peripheral 92 (11) 2 (<1) 69 (8) 3 (<1)
Headache 91 (10) 2 (<1) 59 (7) 3 (<1)
Specific adverse events
Any cardiac adverse event 88 (10) 24 (3) 66 (8) 18 (2)
Atrial fibrillation 16 (2) 3 (<1) 12 (1) 5 (1)
Acute coronary syndromes 7 (1) 7 (1) 4 (<1) 2 (<1)
Acute renal failure 32 (4) 12 (1) 38 (5) 12 (1)
Ischemic or hemorrhagic cerebrovascular event 12 (1) 6 (1) 9 (1) 3 (<1)
Elevation in alanine aminotransferase level 8 (1) 2 (<1) 5 (1) 1 (<1)
Seizure 1 (<1)† 1 (<1)† 1 (<1) 0
* Included in this category are adverse events that were reported in at least 10% of patients in the enzalutamide group at 
a rate that was at least 2 percentage points higher than that in the placebo group.
† This seizure occurred after the data-cutoff date.
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cer that has progressed after androgen-depriva-
tion therapy. The most effective use of these 
therapies (order of administration, duration of 
treatment, and efficacy of combinations) has not 
yet been defined.
In conclusion, in men with minimally symp-
tomatic or asymptomatic metastatic prostate 
cancer who had not received chemotherapy, 
enzalutamide, an oral therapy with an excellent 
side-effect profile, significantly delayed radio-
graphic disease progression or death, the need 
for cytotoxic chemotherapy, and the deteriora-
tion in quality of life and significantly improved 
overall survival.
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